VRCA earnings analysis
What we found in VRCA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Verrica Pharmaceuticals reported Q1 2026 revenue of $5.02 million, exceeding expectations of $4.56 million, driven by a significant increase in product sales of YCANTH. Although there was a net loss of $9.68 million, this was slightly improved compared to the previous year. Management is optimistic about future revenue growth, particularly from ongoing clinical programs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surge
- Total revenue for Q1 2026 reached $5.02 million, up from $3.44 million in Q1 2025, marking a 46.0% increase.
- Product Revenue Growth
- Product revenue, net was $4.29 million, compared to $3.42 million, an increase of 25.4% year-over-year.
- Improved EPS Result
- EPS loss narrowed to -$0.41 from -$0.59, showing a 30.5% improvement.
- Increase in License Revenue
- License revenue increased significantly to $0.73 million from $0.017 million year-over-year.
- Decrease in Interest Expense
- Interest expense dropped from $2.20 million to $0.16 million due to loan settlement.
- Operating Loss Reduced
- Loss from operations decreased from -$8.13 million to -$9.72 million, a slight improvement.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Operating Expenses
- Total operating expenses increased to $14.74 million from $11.57 million, a rise of 27.5%.
- Funding Needs
- The company has substantial doubt regarding its ability to continue as a going concern, as it must secure additional funding before Q1 2027.
- Accumulated Deficit
- As of March 31, 2026, the accumulated deficit reached $334.6 million, indicating ongoing financial strain.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.41
What they said about what is next.
Management anticipates continued revenue growth driven primarily by the demand for YCANTH.
The filing reads better than the one before it.
What came before.
- 10-K · March 11, 2026
- Verrica’s 2025 10-K shows a clear commercial and clinical inflection: annual revenue rose to about $35.0 million in 2025 (sum of quarterly revenues of $3M, $13M, $14M and $5M), driven by commercialization of YCANTH and…
- 10-Q · May 13, 2025
- Verrica reported Q1 2025 revenue of $3,439,000 and a net loss of $9,742,000 (net loss per share $(0.10)), with product revenue up modestly to $3,422,000 while collaboration revenue collapsed to $17,000. Gross margin…
- 10-K · March 11, 2025
- Verrica is an early-commercial dermatology company with one FDA-approved product, YCANTH (VP-102) (approved July 21, 2023) and a Phase 2 oncology asset VP-315 showing promising results (≈51% complete histologic…
- 10-Q · May 13, 2024
- Verrica reported first-quarter product sales following its commercial launch: total revenue of $3,826,000 (product revenue $3,232,000; collaboration $594,000). Despite revenue, the company posted a $20,331,000 net loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VRCA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever